S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
A gold storm is coming… (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
EU migration impasse leaves many refugees out in the cold
Biden's State of the Union to tout policy wins on economy
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
A gold storm is coming… (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
EU migration impasse leaves many refugees out in the cold
Biden's State of the Union to tout policy wins on economy
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
A gold storm is coming… (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
EU migration impasse leaves many refugees out in the cold
Biden's State of the Union to tout policy wins on economy
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
A gold storm is coming… (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
EU migration impasse leaves many refugees out in the cold
Biden's State of the Union to tout policy wins on economy
NASDAQ:NBIX

Neurocrine Biosciences - NBIX Stock Forecast, Price & News

$110.03
+2.03 (+1.88%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$108.44
$110.90
50-Day Range
$107.99
$127.06
52-Week Range
$75.25
$129.29
Volume
1.15 million shs
Average Volume
872,826 shs
Market Capitalization
$10.58 billion
P/E Ratio
193.04
Dividend Yield
N/A
Price Target
$122.24

Neurocrine Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
11.6% Upside
$122.82 Price Target
Short Interest
Healthy
2.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.37mentions of Neurocrine Biosciences in the last 14 days
Based on 26 Articles This Week
Insider Trading
Selling Shares
$13.60 M Sold Last Quarter
Proj. Earnings Growth
108.20%
From $1.83 to $3.81 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

450th out of 1,025 stocks

Biological Products, Except Diagnostic Industry

73rd out of 168 stocks

NBIX stock logo

About Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Stock News Headlines

Pliant Therapeutics Gaps 34% Higher: More Upside To Come? (NBIX)
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Neurocrine Biosciences Q4 2022 Earnings Preview
Neurocrine Biosciences Earnings Preview
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
NBIX Neurocrine Biosciences, Inc.
Voyager, Neurocrine sign new deal worth up to $4.2B
See More Headlines
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Company Calendar

Last Earnings
11/01/2021
Today
2/05/2023
Next Earnings (Confirmed)
2/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NBIX
CUSIP
64125C10
Employees
900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$122.82
High Stock Price Forecast
$150.00
Low Stock Price Forecast
$94.00
Forecasted Upside/Downside
+11.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
16 Analysts

Profitability

Net Income
$89.60 million
Pretax Margin
5.92%

Debt

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$1.24 per share
Book Value
$14.48 per share

Miscellaneous

Free Float
91,904,000
Market Cap
$10.58 billion
Optionable
Optionable
Beta
0.49

Key Executives

  • Kevin Charles GormanKevin Charles Gorman
    Chief Executive Officer & Director
  • Bill Wilson
    Vice President-Information Technology & Operations
  • Matthew C. AbernethyMatthew C. Abernethy
    Chief Financial Officer
  • Dimitri E. GrigoriadisDimitri E. Grigoriadis
    Chief Research Officer
  • Eiry W. RobertsEiry W. Roberts
    Chief Medical Officer













NBIX Stock - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NBIX shares.
View NBIX analyst ratings
or view top-rated stocks.

What is Neurocrine Biosciences' stock price forecast for 2023?

16 brokers have issued 12 month price targets for Neurocrine Biosciences' shares. Their NBIX share price forecasts range from $94.00 to $150.00. On average, they predict the company's stock price to reach $122.82 in the next year. This suggests a possible upside of 11.6% from the stock's current price.
View analysts price targets for NBIX
or view top-rated stocks among Wall Street analysts.

How have NBIX shares performed in 2023?

Neurocrine Biosciences' stock was trading at $119.44 at the start of the year. Since then, NBIX stock has decreased by 7.9% and is now trading at $110.03.
View the best growth stocks for 2023 here
.

Are investors shorting Neurocrine Biosciences?

Neurocrine Biosciences saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 2,590,000 shares, an increase of 15.1% from the December 31st total of 2,250,000 shares. Based on an average daily trading volume, of 819,500 shares, the short-interest ratio is currently 3.2 days. Currently, 2.8% of the shares of the company are sold short.
View Neurocrine Biosciences' Short Interest
.

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 6th 2023.
View our NBIX earnings forecast
.

How can I listen to Neurocrine Biosciences' earnings call?

Neurocrine Biosciences will be holding an earnings conference call on Monday, February 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings data on Monday, November, 1st. The company reported $0.23 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by $0.28. The company had revenue of $296 million for the quarter, compared to the consensus estimate of $297.02 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 4.06% and a net margin of 4.19%. The business's revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.62) earnings per share.

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (0.95%), Allspring Global Investments Holdings LLC (0.52%), Tobam (0.30%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), New York State Common Retirement Fund (0.24%) and Assenagon Asset Management S.A. (0.22%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends
.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $110.03.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $10.58 billion and generates $1.13 billion in revenue each year. The company earns $89.60 million in net income (profit) each year or $0.57 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

The company employs 900 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602.

This page (NASDAQ:NBIX) was last updated on 2/5/2023 by MarketBeat.com Staff